A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
12/2002
12/11/2002	EP1263766A1 Adam polynucleotides, polypeptides, and antibodies
12/11/2002	EP1263760A1 Novel compounds
12/11/2002	EP1263756A2 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
12/11/2002	EP1263755A2 Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
12/11/2002	EP1263754A1 INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
12/11/2002	EP1263730A1 Amine derivatives for the treatment of apoptosis
12/11/2002	EP1263729A1 Azacyclic compounds for use in the treatment of serotonin related diseases
12/11/2002	EP1263726A1 N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
12/11/2002	EP1263725A1 Novel compounds
12/11/2002	EP1263724A1 Novel compounds
12/11/2002	EP1263720A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
12/11/2002	EP1263475A2 Synthetic oligonucleotides as inducers of erythroid differentiation
12/11/2002	EP1263472A2 Modification of biopolymers for improved drug delivery
12/11/2002	EP1263464A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function
12/11/2002	EP1263463A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cells
12/11/2002	EP1263427A1 Il-8 receptor antagonists
12/11/2002	EP1263300A1 Improvements in or relating to solubilisation of flavonols
12/11/2002	EP1149104B1 Pyrrolobenzodiazepine carboxyamide vasopressin agonists
12/11/2002	EP1095025B1 Benzimidazoles, production thereof and use thereof as medicaments
12/11/2002	EP1071433B1 2',2'-difluoronucleosides for immunosuppressive therapy and combined pharmaceutical compositions
12/11/2002	EP1017378B1 Amide derivatives for the treatment of diseases mediated by cytokines
12/11/2002	EP0981521B1 Novel macrocyclic compounds as metalloprotease inhibitors
12/11/2002	EP0925294B1 Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and method of reducing tnf-alpha levels
12/11/2002	EP0802985B1 Cell cycle regulated repressor and dna element
12/11/2002	CN1384876A Modular transport systems for molecular substances and production and use thereof
12/11/2002	CN1384822A Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-3,3-diphenylpropionate and use thereof endothelin antagonist
12/11/2002	CN1384814A Phenoxy carboxylic acid compounds and compositions for delivering active agents
12/11/2002	CN1384733A Dry powder compositions having improved dispersivity
12/11/2002	CN1384707A Preserving hemoglobin blood substitute with transparent overwrap
12/11/2002	CN1384116A New-type alpha-interferon
12/11/2002	CN1384112A High-efficient production process of genetically engineered medicine Angel thrombus-resisting factor
12/11/2002	CN1384100A Benzo-1,3-dioxole and benzofuran substituted pentazane derivative
12/11/2002	CN1383829A Compound folic acid prepn for preventing and treating homocysteinemia and relevant diseases
12/11/2002	CN1383823A Method of applying MEK inhibitor to treat or inhibit neutrophil chemotaxis
12/10/2002	US6492494 Method of making a fibrin sealant comprising alpha-2-antiplasmin
12/10/2002	US6492408 Peptidomimetic inhibitors of intercellular adhesion molecules binding to leukointegrins, such as lfa-1 and mac-1
12/10/2002	US6492402 Anticoagulants; peptide derivatives having high antithrombotic activity and oral bioavailability
12/10/2002	US6492393 Compounds useful as anti-inflammatory agents
12/10/2002	US6492384 Imidazo (4,5-C) pyridine-4-one derivatives with factor XA inhibiting effect
12/10/2002	US6492379 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
12/10/2002	US6492376 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
12/10/2002	US6492372 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
12/10/2002	US6492368 Benzamidine derivatives as factor XA inhibitors
12/10/2002	US6492367 Sulfamato hydroxamic acid metalloprotease inhibitor
12/10/2002	US6492358 For treatment of sexual disorders, male erectile dysfunction
12/10/2002	US6491907 Genetic engineered chimera particles comprising capsids from adeno-associated virus and genome inverted terminal repeat sequences as vectors for supplying and expressing nucleotide sequence in cells
12/10/2002	CA2230445C Fibrinogen receptor antagonists and medicinal preparations containing the same as the active ingredient
12/09/2002	WO2001096366A2 Dipeptide inhibitors for the blood-clotting factor xa
12/09/2002	CA2412181A1 Dipeptide inhibitors for the blood-clotting factor xa
12/08/2002	CA2817619A1 Methods of administering anti-tnf.alpha. antibodies
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097063A1 Production of bioavailable folic acid
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097046A2 B7 related protein-2 molecules and uses thereof
12/05/2002	WO2002097044A2 Alternative splice forms of proteins as basis for multiple therapeutic modalities
12/05/2002	WO2002097032A2 Proteins associated with cell growth, differentiation, and death
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096926A1 Modulators of pharmacological agents
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096873A1 Isoindole and isoquinoline derivatives as inhibitors of factor xa
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096516A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
12/05/2002	WO2002096471A2 Viral inactivation process using antioxidant
12/05/2002	WO2002096443A1 Use of a product comprising catuama extract as an antithromboembolic agent
12/05/2002	WO2002096442A1 Use of a product comprising catuama exptract as an antidepressant agent and in anxiety disorders
12/05/2002	WO2002096441A1 Use of a product comprising catuama extract as an antioxidant and cerebral vasodilator agent
12/05/2002	WO2002096428A1 Pharmaceutical combinations
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096425A1 Utilization of bicyclic heterocycles for the treatment and prevention of arterial thrombotic diseases
12/05/2002	WO2002096390A1 Neutral-cationic lipid for systemic delivery of factor viii gene
12/05/2002	WO2002096366A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	WO2002096363A2 Method for treating fibrotic diseases or other indications
12/05/2002	WO2002096362A2 Method for treating fibrotic diseases or other indications vi
12/05/2002	WO2002096358A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002066450A3 Anthrone derivatives and their use as ink inhibitors
12/05/2002	WO2002065978A3 Functional agent for decomposing nicotine and method of preparing the same
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof
12/05/2002	WO2002020766A3 G-csf analog compositions and methods
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	US20020183527 Process for the preparation of amorphous atorvastatin
12/05/2002	US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002	US20020183492 Isolation of biopolymers from human serum albumin; obtain human serum albumin, expose to ion exchange resin, elute and recover biopolymer
12/05/2002	US20020183398 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
12/05/2002	US20020183384 Administering sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt for therapy of disease or a disorder responsive to inhibition of nuclear factor- kappa B (NF- kappa B)
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183360 Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels
12/05/2002	US20020183349 For therapy and prophylaxis of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes, sleep apnea
12/05/2002	US20020183346 Tricyclic androgen receptor modulator compounds and methods
12/05/2002	US20020183324 Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
12/05/2002	US20020183269 Novel compounds
12/05/2002	US20020183254 For inhibiting blood coagulation
12/05/2002	US20020182587 Detection of modulators of cell proliferation; obtain cells, monitor cell proliferation, incubate cell with modulator, detect adjustment in cell proliferation
12/05/2002	US20020182582 Process for preparing agents containing virus-inactivated vitamin K-dependent plasma components as well as protein C and protein S by membrane chromatography
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance

1 ... 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 ... 671